China NT Pharma Group Company Limited (01011.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−30.3x

Market Cap

HKD 280.42M

MomentumView details →

1D Return

−1.19%

YTD Return

−48.78%

RSI (14)

55.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−30.3x

Market Cap

HKD 280.42M

RSI (14)

55.7

MomentumView details →

1D Return

−1.19%

YTD Return

−48.78%

ProfitabilityView details →

Gross Margin

28.45%

Net Margin

−181.39%

EBITDA Margin

−37.94%

ROE (TTM)

88.31%

ROA (TTM)

−15.28%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

−56.76%

EPS YoY

+64.67%

FCF YoY

—

Revenue CAGR 3Y

−51.14%

EPS CAGR 3Y

+78.90%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−3.01x

Current Ratio

0.05x

Quick Ratio

0.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

+40.00%

Financials snapshotView financials →

Revenue (TTM)

54.16M

Net Income (TTM)

−98.24M

Op. CF (TTM)

—

Latest newsMore news →

Zhongke Tianyuan issued a profit warning, expecting its attributable loss for the six months ending June 2026 to narrow to approximately RMB 3.72 million from RMB 7.85 million a year earlier.11d ago

Tailing Medicine reported interim results for the six months ended June 2026, with revenue up 97.3% year-on-year to RMB 23.67 million and net loss widening to RMB 18.43 million from RMB 16.91 million a year earlier.15d ago

Similar companies

Cardiol Therapeutics Inc.CRDL Aurora Cannabis Inc.ACB Emergent BioSolutions Inc.EBS Embecta Corp.EMBC SIGA Technologies, Inc.SIGA Wai Yuen Tong Medicine Holdings Limited00897.HK Find similar companies →

Latest newsMore news →

Zhongke Tianyuan issued a profit warning, expecting its attributable loss for the six months ending June 2026 to narrow to approximately RMB 3.72 million from RMB 7.85 million a year earlier.11d ago Tailing Medicine reported interim results for the six months ended June 2026, with revenue up 97.3% year-on-year to RMB 23.67 million and net loss widening to RMB 18.43 million from RMB 16.91 million a year earlier.15d ago